<DOC>
	<DOC>NCT03049774</DOC>
	<brief_summary>The aim of this retrospective study is to review and describe the safety and the efficacy of recombinant human interleukin-11 (I) i (Baijieyi), using information already recorded in 20 medical records, The time periods include May 8th of 2008 to december 31st of 2016.</brief_summary>
	<brief_title>A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<criteria>1. prescriptions explicitly given to the injection of Baijieyi; 2. confirmed by histopathological or cytological examination of malignant tumors and chemotherapy; 3. treatment: platelet count had reached below 75Ã—10^9/L after the treatment of chemotherapy and before using Baijieyi; prevention: patients with chemotherapy at the beginning of the preventive administration of BaiJieyi, and chemotherapy is same with previous cycle; 4. male or female, aged 1885 years; 5. The main research information required is complete. 1. using other platelets of chemicals or biological products in the in the chemotherapy cycle used Baijieyi; 2. using drugs which can cause thrombocytopenia in the in the chemotherapy cycle used Baijieyi; 3. bone marrow dysfunction or bone marrow involvement; 4. There are other causes of thrombocytopenia, such as aplastic anemia, acute leukemia, radiation sickness, immune thrombocytopenic purpura, and hypersplenism, in the course of the use of Baijieyi.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>